AbCellera Biologics Inc. (ABCL) - Latest Market Data

Price & Market Data

Price: $5.20

Daily Change: +$0.06 / 1.15%

Daily Range: $5.05 - $5.43

Market Cap: $1,587,952,000

Daily Volume: 6,465,893

Performance Metrics

1 Week: 24.65%

1 Month: 31.11%

3 Months: 68.04%

6 Months: 55.26%

1 Year: 168.2%

YTD: 55.26%

About AbCellera Biologics Inc. (ABCL)

Comprehensive market data and analysis for AbCellera Biologics Inc. (ABCL). Current price: 5.20, daily change: +$0.06 / 1.15%. Market cap: 1,587,952,000. View detailed YTD, 1-week, and 1-month performance.

Company Details

Employees: 562

Sector: Health technology

Industry: Biotechnology

Country: Canada

Details

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Selected stocks

Brilliant Earth Group, Inc. (BRLT)

BioNexus Gene Lab Corp (BGLC)

Bit Origin Limited (BTOG)

Surf Air Mobility Inc. (SRFM)

Avalon GloboCare Corp. (ALBT)